These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 34416506

  • 1. Exploring phenylcarbamoylazinane-1,2,4-triazole thioethers as lipoxygenase inhibitors supported with in vitro, in silico and cytotoxic studies.
    Shahid W, Ashraf M, Saleem M, Bashir B, Muzaffar S, Ali M, Kaleem A, Aziz-Ur-Rehman, Amjad H, Bhattarai K, Riaz N.
    Bioorg Chem; 2021 Oct; 115():105261. PubMed ID: 34416506
    [Abstract] [Full Text] [Related]

  • 2. Probing phenylcarbamoylazinane-1,2,4-triazole amides derivatives as lipoxygenase inhibitors along with cytotoxic, ADME and molecular docking studies.
    Muzaffar S, Shahid W, Riaz N, Saleem M, Ashraf M, Aziz-Ur-Rehman, Bashir B, Kaleem A, Al-Rashida M, Baral B, Bhattarai K, Gross H.
    Bioorg Chem; 2021 Feb; 107():104525. PubMed ID: 33317840
    [Abstract] [Full Text] [Related]

  • 3. Molecular hybrids of substituted phenylcarbamoylpiperidine and 1,2,4-triazole methylacetamide as potent 15-LOX inhibitors: Design, synthesis, DFT calculations and molecular docking studies.
    Nawaz Z, Riaz N, Saleem M, Iqbal A, Abida Ejaz S, Bashir B, Muzaffar S, Ashraf M, Aziz-Ur-Rehman, Sajjad Bilal M, Krishna Prabhala B, Sajid S.
    Bioorg Chem; 2024 Feb; 143():106984. PubMed ID: 38056389
    [Abstract] [Full Text] [Related]

  • 4. Identification of phenylcarbamoylazinane-1,3,4-oxadiazole amides as lipoxygenase inhibitors with expression analysis and in silico studies.
    Bashir B, Shahid W, Ashraf M, Saleem M, Aziz-Ur-Rehman, Muzaffar S, Imran M, Amjad H, Bhattarai K, Riaz N.
    Bioorg Chem; 2021 Oct; 115():105243. PubMed ID: 34403937
    [Abstract] [Full Text] [Related]

  • 5. Investigations of p-tolyloxy-1,3,4-oxadiazole propionamides as soybean 15-lipoxygenase inhibitors in comforting with in vitro and in silico studies.
    Bashir B, Riaz N, Ejaz SA, Saleem M, Iqbal A, Ashraf M, Ejaz S, -Rehman AU, Aziz M, Bhattarai K.
    J Biomol Struct Dyn; 2023 Oct; 41(24):15549-15568. PubMed ID: 36946200
    [Abstract] [Full Text] [Related]

  • 6. Assessing p-tolyloxy-1,3,4-oxadiazole acetamides as lipoxygenase inhibitors assisted by in vitro and in silico studies.
    Bashir B, Riaz N, Abida Ejaz S, Saleem M, Ashraf M, Iqbal A, Muzaffar S, Ejaz S, Aziz-Ur-Rehman, Mohammad Kashif Mahmood H, Bhattarai K.
    Bioorg Chem; 2022 Dec; 129():106144. PubMed ID: 36116325
    [Abstract] [Full Text] [Related]

  • 7. Probing N-substituted 4-(5-mercapto-4-ethyl-4H-1,2,4-triazol-3-yl)-N-phenylpiperdine-1-carboxamides as potent 15-LOX inhibitors supported with ADME, DFT calculations and molecular docking studies.
    Nawaz Z, Riaz N, Saleem M, Iqbal A, Ejaz SA, Muzaffar S, Bashir B, Ashraf M, Rehman AU, Bilal MS, Prabhala BK, Sajid S.
    Heliyon; 2024 Sep 15; 10(17):e35278. PubMed ID: 39281606
    [Abstract] [Full Text] [Related]

  • 8. Expanding the anticancer potential of 1,2,3-triazoles via simultaneously targeting Cyclooxygenase-2, 15-lipoxygenase and tumor-associated carbonic anhydrases.
    Elzahhar PA, Abd El Wahab SM, Elagawany M, Daabees H, Belal ASF, El-Yazbi AF, Eid AH, Alaaeddine R, Hegazy RR, Allam RM, Helmy MW, Bahaa Elgendy, Angeli A, El-Hawash SA, Supuran CT.
    Eur J Med Chem; 2020 Aug 15; 200():112439. PubMed ID: 32485532
    [Abstract] [Full Text] [Related]

  • 9. Discovery of novel hybrids of diaryl-1,2,4-triazoles and caffeic acid as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase for cancer therapy.
    Cai H, Huang X, Xu S, Shen H, Zhang P, Huang Y, Jiang J, Sun Y, Jiang B, Wu X, Yao H, Xu J.
    Eur J Med Chem; 2016 Jan 27; 108():89-103. PubMed ID: 26638042
    [Abstract] [Full Text] [Related]

  • 10. Click chemistry synthesis, biological evaluation and docking study of some novel 2'-hydroxychalcone-triazole hybrids as potent anti-inflammatory agents.
    Boshra AN, Abdu-Allah HHM, Mohammed AF, Hayallah AM.
    Bioorg Chem; 2020 Jan 27; 95():103505. PubMed ID: 31901755
    [Abstract] [Full Text] [Related]

  • 11. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA, Sakr H, Ayyad RRA, El-Adl K, Ali MM, Khedr F.
    Anticancer Agents Med Chem; 2018 Jan 27; 18(8):1184-1196. PubMed ID: 29651967
    [Abstract] [Full Text] [Related]

  • 12. Synthesis, cytotoxic, anti-lipoxygenase and anti-acetylcholinesterase capacities of novel derivatives from harmine.
    Filali I, Belkacem MA, Ben Nejma A, Souchard JP, Ben Jannet H, Bouajila J.
    J Enzyme Inhib Med Chem; 2016 Jan 27; 31(sup1):23-33. PubMed ID: 27028352
    [Abstract] [Full Text] [Related]

  • 13. Synthesis, molecular properties, anti-inflammatory and anticancer activities of novel 3-hydroxyflavone derivatives.
    Znati M, Bordes C, Forquet V, Lantéri P, Ben Jannet H, Bouajila J.
    Bioorg Chem; 2019 Aug 27; 89():103009. PubMed ID: 31158579
    [Abstract] [Full Text] [Related]

  • 14. 1,2,3-triazole tethered Indole-3-glyoxamide derivatives as multiple inhibitors of 5-LOX, COX-2 & tubulin: Their anti-proliferative & anti-inflammatory activity.
    Naaz F, Preeti Pallavi MC, Shafi S, Mulakayala N, Shahar Yar M, Sampath Kumar HM.
    Bioorg Chem; 2018 Dec 27; 81():1-20. PubMed ID: 30081353
    [Abstract] [Full Text] [Related]

  • 15. Identification of NSAIDs as lipoxygenase inhibitors through highly sensitive chemiluminescence method, expression analysis in mononuclear cells and computational studies.
    Shahid W, Ejaz SA, Al-Rashida M, Saleem M, Ahmed M, Rahman J, Riaz N, Ashraf M.
    Bioorg Chem; 2021 May 27; 110():104818. PubMed ID: 33784531
    [Abstract] [Full Text] [Related]

  • 16. Design, synthesis, molecular docking and anti-proliferative evaluations of [1,2,4]triazolo[4,3-a]quinoxaline derivatives as DNA intercalators and Topoisomerase II inhibitors.
    El-Adl K, El-Helby AA, Sakr H, Elwan A.
    Bioorg Chem; 2020 Dec 27; 105():104399. PubMed ID: 33113414
    [Abstract] [Full Text] [Related]

  • 17. Design, synthesis, biological evaluation and docking studies of new 3-(4,5-dihydro-1H-pyrazol/isoxazol-5-yl)-2-phenyl-1H-indole derivatives as potent antioxidants and 15-lipoxygenase inhibitors.
    ElBordiny HS, El-Miligy MM, Kassab SE, Daabees H, Mohamed Ali WA, Abdelhamid Mohamed El-Hawash S.
    Eur J Med Chem; 2018 Feb 10; 145():594-605. PubMed ID: 29339254
    [Abstract] [Full Text] [Related]

  • 18. Design, Synthesis and Antiproliferative Evaluation of Novel 1,2,4-Triazole/Schiff Base Hybrids with EGFR and B-RAF Inhibitory Activities.
    El-Sherief HAM, Youssif BGM, Abdelazeem AH, Abdel-Aziz M, Abdel-Rahman HM.
    Anticancer Agents Med Chem; 2019 Feb 10; 19(5):697-706. PubMed ID: 30582484
    [Abstract] [Full Text] [Related]

  • 19. Synthesis and biological evaluation of purine-pyrazole hybrids incorporating thiazole, thiazolidinone or rhodanine moiety as 15-LOX inhibitors endowed with anticancer and antioxidant potential.
    Afifi OS, Shaaban OG, Abd El Razik HA, Shams El-Dine SEA, Ashour FA, El-Tombary AA, Abu-Serie MM.
    Bioorg Chem; 2019 Jun 10; 87():821-837. PubMed ID: 30999135
    [Abstract] [Full Text] [Related]

  • 20. Targeting new N-furfurylated 4-chlorophenyl-1,2,4-triazolepropionamide hybrids as potential 15-lipoxygenase inhibitors supported with in vitro and in silico studies.
    Yasin M, Shahid W, Ashraf M, Saleem M, Muzaffar S, Ejaz SA, Mahmood HMK, Bhattarai K, Riaz N.
    J Biomol Struct Dyn; 2023 Jul 10; 41(11):5166-5182. PubMed ID: 35699270
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.